Investors of Baxter International Inc. Encouraged to Lead Securities Fraud Lawsuit

Baxter International Inc. Securities Fraud Lawsuit

On November 20, 2025, the Rosen Law Firm, a distinguished global investor rights law firm, issued an important reminder for investors involved with Baxter International Inc. (NYSE: BAX). If you purchased common stocks of Baxter between February 23, 2022, and July 30, 2025, you are invited to participate in a class action lawsuit. The deadline to appoint a lead plaintiff in this case is December 15, 2025.

Who Should Act

This message is particularly relevant for individuals who bought shares of Baxter during the aforementioned class period. You may be entitled to compensation without any upfront costs, all under a contingency fee arrangement, which means you only pay if you possibly win.

What To Do Next

To join the class action lawsuit against Baxter, you can either visit Rosen Law's website or reach out to attorney Phillip Kim at the toll-free number 866-767-3653. Alternatively, you can email him at [email protected] for further details concerning your eligibility and next steps. A prior case has already been filed, so if you wish to take the lead in this lawsuit, you must act before the specified deadline.

Background of the Lawsuit

The core of the lawsuit revolves around claims that Baxter International misled its investors during the class action period. The allegations suggest that the company failed to disclose critical information regarding the Novum LVP device, which had severe systemic defects resulting in malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids. These defects pose significant risks, potentially leading to serious injuries or even fatalities for patients relying on these devices.

Furthermore, it is claimed that Baxter was aware of numerous instances where the device malfunctioned, causing injury or death, yet took insufficient steps to address these issues effectively. Customer alerts were deemed inadequate when the persistent design flaws continued to cause serious patient harm. As these realities came to light, Baxter's previous assertions concerning the safety and efficacy of Novum LVPs were revealed to be materially misleading.

Choosing the Right Legal Representation

When it comes to filing a class action lawsuit, selecting the right counsel is pivotal. The Rosen Law Firm specializes in securities class actions and is known for their successful track record in these cases. They encourage investors to seek firms with proven experience and resources, emphasizing that many law firms may only serve as intermediaries without the necessary litigation expertise.

The Rosen Law Firm has a long-standing history of representing investors worldwide and has previously secured record-breaking settlements, including the largest securities class action against a Chinese company. The firm consistently ranks as a top performer in securities class action settlements, having recovered hundreds of millions of dollars for investors.

Important Note for Investors

It's crucial to note that as of now, no class has been certified for this lawsuit. Until such a certification is achieved, any investors who wish to be represented by counsel need to secure their own legal representation. Alternatively, investors may also choose to remain uninvolved while retaining the right to claim in any potential recovery should the opportunity arise.

For ongoing updates and more information on this lawsuit, stay connected with the Rosen Law Firm through their social media platforms, including LinkedIn, Twitter, and Facebook.

In summary, this announcement is a valuable opportunity for Baxter International investors to take action and potentially seek compensation for losses incurred during the defined class period. It's an essential time for stakeholders to engage and protect their interests as the situation develops.

Contact Details
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Fax: (212) 202-3827
Email: [email protected]
Website: www.rosenlegal.com